Antibodies to a putative HIV gp41 immunosuppressive peptide, pHIVIS (583-599), do not correlate significantly with outcome in HIV infection.
We have studied the prevalence of antibodies to peptides derived from the transmembrane protein of HIV, gp41. Previous work has suggested that the presence of antibodies to the gp41 peptide known as pHIVIS (env 583-599) is associated with protection from immunosuppression in HIV infection. We studied 171 sequential sera from 55 HIV-1-infected people in various clinical stages of disease. There was no significant association between antibodies to pHIVIS and clinical status in this study. Although pHIVIS has sequence similarity to the putative immunosuppressive region of the C-type oncornaviruses (p15E), antibodies to this peptide do not appear to be associated with protection from immunosuppression in natural HIV infection.
Cheingsong-Popov
R
R
Department of Infectious Diseases, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.
Panagiotidi
C
C
Caun
K
K
Klasse
P J
PJ
Pipkorn
R
R
Blomberg
J
J
Weber
J
J
D000595:Amino Acid Sequence; D015483:HIV Antibodies; D015700:HIV Envelope Protein gp41 / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology*; D006801:Humans; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000276:immunology*
D015483:HIV Antibodies; D015700:HIV Envelope Protein gp41; D010446:Peptide Fragments